The firm aims to launch an early-access program by the end of the year, followed by a second white paper before the JP Morgan Healthcare Conference in January.
The firm said the New York State approval for the two tests comes soon after it launched Sema4 Signal, a family of precision oncology products and services.
Startup BioLizard will develop the algorithm to help Novigenix migrate its immuno-transcriptiomic assay for early colorectal cancer detection to a new NGS-based platform.
The company has formalized an existing relationship by acquiring Pharmatech, hoping to directly integrate the firm's "right on time" trial matching service with its own molecular testing.
Clinical researchers at AACR discussed a wide range of approaches focusing on several different potential use-cases in the detection or assessment of early cancers.
The company believes it can provide tests to predict patients' responsiveness to specific drugs akin to the molecular diagnostics that have now swelled the oncology space.
